ALAnders Hostrup Larsen

Anders Hostrup Larsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders Hostrup Larsen has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hydralazine-isosorbide dinitrate in chronic heart failure with reduced ejection fraction: the H-HeFT trial

    by Lars Køber, Kim Wadt Skak-Hansen, Anders Hostrup Larsen, Søren Vraa, Morten Schou, Dan Eik Høfsten, Jens Refsgaard, Flemming Steffensen, Christian Hassager, Erik Parner, et al.

    Background and Aims: Hydralazine-isosorbide dinitrate (H-ISDN) has shown benefit in earlier randomized trials of patients with reduced left ventricular ejection fraction (LVEF) and chronic heart failure. This trial tested if H-ISDN could reduce worsening heart failure or mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF) receiving contemporary treatment. Methods: The Hydralazine-Isosorbide Dinitrate in Patients With Chronic Heart Failure Trial (H-HeFT) was a multicentre, randomized (1:1), double-blind, placebo-controlled trial in patients with HFrEF at 23 Danish hospitals (New York Heart Association class II–IV, elevated N-terminal pro-B-type natriuretic peptide and LVEF ≤40%). Target treatment was hydralazine 75 mg/isosorbide dinitrate 40 mg three times a day (t.i.d). The primary endpoint was a composite of hospitalization with worsening heart failure, an urgent outpatient visit resulting in intravenous/metolazone therapy for heart failure, heart transplantation, left ventricular assist device implantation, or death. Secondary endpoints included components of the primary outcome. Results: Overall, 592 predominantly White patients (median age 72 years, 18% women) were randomized with a mean follow-up of 3.7 years. The primary outcome occurred in 90 of 294 patients (30.6%) in the H-ISDN group and in 91 of 298 patients (30.5%) in the placebo group [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.67–1.21; P = .48]. There were 57 deaths in the H-ISDN group vs 72 in the placebo group (HR 0.72; 95% CI 0.51–1.02); worsening heart failure events occurred in 52 vs 47 patients (HR 1.01; 95% CI 0.68–1.50). Conclusions: Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF ≤40%.


  • Open Access

    Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels

    by Anders Hostrup Larsen, Tore Bjerregaard Stage, Mette Marie Hougaard Christensen, Søren Feddersen, Flemming Nielsen, Helene Nørrelund, Jørgen Frøkiær, Niels Jessen, Kim Brøsen, Henrik Wiggers

  • Open Access

    Metformin inhibits proliferation of residing fibroadipogenic progenitor cells from failing human hearts

    by Anders Hostrup Larsen, Lin Lin, Andreas Buch Møller, Jean Farup, Lars Poulsen Tolbod, Tine Billeskov, Jonas Brorson, Elias Immanuel Ordell Sundelin, Steen Jakobsen, Helene Nørrelund, et al.

    Introduction: Evidence from randomized trials indicates beneficial effects of metformin treatment in heart failure with reduced ejection fraction (HFrEF), but mechanisms of action remain elusive. We investigated myocardial metformin distribution in vivo in HFrEF patients and explored its effects on cardiac fibrogenic progenitor cells from human HFrEF hearts in vitro. Methods: We assessed myocardial metformin distribution and its dependency on myocardial viability in seven HFrEF patients (ejection fraction: 36 ± 8%; median age: 67 years) using 11C-metformin positron emission tomography (PET), 15O-H2O-PET, and exercise stress echocardiography. We characterized myocardial cellular composition by fluorescence-activated cell sorting and single-cell RNA sequencing (scRNA-seq) on mononuclear cells isolated from explanted left ventricles from four HFrEF patients and four control human hearts. A population of fibroadipogenic progenitor cells (FAPs) was identified and incubated after differentiation with metformin to test the effects on proliferation. Results: Myocardial 11C-metformin kinetics were best described by reversible two-tissue-compartment kinetics. Global myocardial metformin net influx rate was 0.012 ± 0.007 ml ml−1 min−2, and the myocardium-to-blood ratio was 1.24 (95% confidence intervals: 1.03–1.44; P < .001) after 90 min. Regional myocardial metformin net influx correlated inversely with myocardial viability (r = −0.65, P = .04). By scRNA-seq, we identified cardiac FAPs expressing CD34 and PDGFRA, which transformed into extracellular matrix-forming myogenic cells upon activation. Incubation with metformin in clinically relevant doses (0.1 mM) inhibited FAP proliferation by 25%. Conclusion: Myocardial metformin uptake in HFrEF is marginal and confined to less viable and fibrotic regions. Cardiac FAPs are resident in human HFrEF myocardium and exhibit fibrogenic potential. Metformin inhibits FAP activation and proliferation at clinically relevant concentrations. These findings suggest that metformin may attenuate adverse left ventricular remodelling by targeting cardiac FAPs. Clinical trial registration: https://clinicaltrials.gov. Unique identifier: NCT03122769.

  • Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study

    by Anders Hostrup Larsen, Henrik Wiggers, Ole Lindgård Dollerup, Nichlas Riise Jespersen, Nils Henrik Hansson, Jørgen Frøkiær, Kim Brøsen, Helene Nørrelund, Hans Erik Bøtker, Niels Møller, et al.

    Purpose The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced alterations in whole-body insulin sensitivity and substrate metabolism. Methods Eighteen HF patients with reduced ejection fraction and without diabetes (median age, 65 (interquartile range 55–68); ejection fraction 39 ± 6%; HbA1c 5.5 to 6.4%) were randomized to receive metformin (n = 10) or placebo (n = 8) for 3 months. We studied the effects of metformin on whole-body insulin sensitivity using a two-step hyperinsulinemic euglycemic clamp incorporating isotope-labeled tracers of glucose, palmitate, and urea. Substrate metabolism and skeletal muscle mitochondrial respiratory capacity were determined by indirect calorimetry and high-resolution respirometry, and body composition was assessed by bioelectrical impedance analysis. The primary outcome measure was change in insulin sensitivity. Results Compared with placebo, metformin treatment lowered mean glycated hemoglobin levels (absolute mean difference, − 0.2%; 95% CI − 0.3 to 0.0; p = 0.03), reduced body weight (− 2.8 kg; 95% CI − 5.0 to − 0.6; p = 0.02), and increased fasting glucagon levels (3.2 pmol L−1; 95% CI 0.4 to 6.0; p = 0.03). No changes were observed in whole-body insulin sensitivity, endogenous glucose production, and peripheral glucose disposal or oxidation with metformin. Equally, resting energy expenditure, lipid and urea turnover, and skeletal muscle mitochondrial respiratory capacity remained unaltered. Conclusion Increased myocardial efficiency during metformin treatment is not mediated through improvements in insulin action in HF patients without diabetes. Clinical Trial Registration URL: https://clinicaltrials.gov. Unique identifier: NCT02810132. Date of registration: June 22, 2016.


  • A Randomised, Double-Blind, Placebo-Controlled Trial of Metformin on Myocardial Efficiency in Insulin-Resistant Chronic Heart Failure Patients without Diabetes

    by Anders Hostrup Larsen, Niels Jessen, Helene Nørrelund, Lars Poulsen Tolbod, Hendrik Johannes Harms, Søren Feddersen, Flemming Nielsen, Kim Brøsen, Nils Henrik Hansson, Jørgen Frøkiær, et al.

    Aims The present study tested the hypothesis that metformin treatment may increase myocardial efficiency (stroke work/myocardial oxygen consumption) in insulin‐resistant patients with heart failure and reduced ejection fraction (HFrEF) without diabetes. Methods and results Thirty‐six HFrEF patients (ejection fraction 37 ± 8%; median age 66 years) were randomised to metformin (n = 19) or placebo (n = 17) for 3 months in addition to standard heart failure therapy. The primary endpoint was change in myocardial efficiency expressed as the work metabolic index (WMI), assessed by 11C‐acetate positron emission tomography and transthoracic echocardiography. Compared with placebo, metformin treatment (1450 ± 550 mg/day) increased WMI [absolute mean difference, 1.0 mmHg·mL·m‐2·106; 95% confidence interval (CI) 0.1 to 1.8; P = 0.03], equivalent to a 20% relative efficiency increase. Patients with above‐median plasma metformin levels displayed greater WMI increase (25% vs. –4%; P = 0.02). Metformin reduced myocardial oxygen consumption (–1.6 mL O2·100 g‐1·min‐1; P = 0.014). Cardiac stroke work was preserved (–2 J; 95% CI –11 to 7; P = 0.69). Metformin reduced body weight (–2.2 kg; 95% CI –3.6 to –0.8; P = 0.003) and glycated haemoglobin levels (–0.2%; 95% CI –0.3 to 0.0; P = 0.02). Changes in resting and exercise ejection fraction, global longitudinal strain, and exercise capacity did not differ between groups. Conclusion Metformin treatment in non‐diabetic HFrEF patients improved myocardial efficiency by reducing myocardial oxygen consumption. Measurement of circulating metformin levels differentiated responders from non‐responders. These energy‐sparing effects of metformin encourage further large‐scale investigations in heart failure patients without diabetes.


  • Open Access

    Myocardial strain assessed by feature tracking cardiac magnetic resonance in patients with a variety of cardiovascular diseases – A comparison with echocardiography

    by Kasper Pryds, Anders Hostrup Larsen, Mona Sahlholdt Hansen, Anne Yoon Krogh Grøndal, Rasmus Stilling Tougaard, Nils Henrik Hansson, Tor Skibsted Clemmensen, Brian Bridal Løgstrup, Henrik Wiggers, Won Yong Kim, et al.

    Myocardial deformation assessed by speckle tracking echocardiography (STE) is increasingly used for diagnosis, monitoring and prognosis in patients with clinical and pre-clinical cardiovascular diseases. Feature tracking cardiac magnetic resonance (FT-CMR) also allows myocardial deformation analysis. To clarify whether the two modalities can be used interchangeably, we compared myocardial deformation analysis by FT-CMR with STE in patients with a variety of cardiovascular diseases and healthy subjects. We included 40 patients and 10 healthy subjects undergoing cardiac magnetic resonance and echocardiographic examination for left ventricular volumetric assessment. We studied patients with heart failure and reduced ejection fraction (n = 10), acute perimyocarditis (n = 10), aortic valve stenosis (n = 10), and previous heart transplantation (n = 10) by global longitudinal (GLS), radial (GRS) and circumferential strain (GCS). Myocardial deformation analysis by FT-CMR was feasible in all but one participant. While GLS, GRS and GCS measured by FT-CMR correlated overall with STE (r = 0.74 and p < 0.001, r = 0.58 and p < 0.001, and r = 0.76 and p < 0.001), the correlations were not consistent within subgroups. GLS was systematically lower, whereas GRS and GCS were higher by FT-CMR compared to STE (p = 0.04 and p < 0.0001). Inter- and intra-observer reproducibility were comparable for FT-CMR and STE overall and across subgroups. In conclusion, myocardial deformation can be evaluated using FT-CMR applied to routine cine-CMR images in patients with a variety of cardiovascular diseases. However, correlation between FT-CMR and STE was modest and agreement was not optimal due to systematic bias regarding GLS and GCS. Consequently, FT-CMR and STE should not be used interchangeably for myocardial strain evaluation.


  • Abnormal Coronary Flow Velocity Reserve and Decreased Myocardial Contractile Reserve Are Main Factors in Relation to Physical Exercise Capacity in Cardiac Amyloidosis

    by Tor Skibsted Clemmensen, Hans Eiskjær, Henning Mølgaard, Anders Hostrup Larsen, Jens Soerensen, Niels Frost Andersen, Lars Poulsen Tolbod, Hendrik J. Harms, Steen Hvitfeldt Poulsen